ENDRA Life Sciences (NDRA) EBIT (2016 - 2021)
Historic EBIT for ENDRA Life Sciences (NDRA) over the last 6 years, with Q4 2021 value amounting to -$3.1 million.
- ENDRA Life Sciences' EBIT fell 3625.0% to -$3.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$11.5 million, marking a year-over-year increase of 3.14%. This contributed to the annual value of -$10.8 million for FY2024, which is 281.74% down from last year.
- Latest data reveals that ENDRA Life Sciences reported EBIT of -$3.1 million as of Q4 2021, which was down 3625.0% from -$2.7 million recorded in Q3 2021.
- ENDRA Life Sciences' EBIT's 5-year high stood at -$360697.0 during Q1 2017, with a 5-year trough of -$3.3 million in Q3 2020.
- Over the past 5 years, ENDRA Life Sciences' median EBIT value was -$2.6 million (recorded in 2019), while the average stood at -$2.4 million.
- Its EBIT has fluctuated over the past 5 years, first plummeted by 68670.41% in 2018, then skyrocketed by 2799.16% in 2020.
- Quarter analysis of 5 years shows ENDRA Life Sciences' EBIT stood at -$2.3 million in 2017, then increased by 12.79% to -$2.0 million in 2018, then crashed by 56.31% to -$3.1 million in 2019, then increased by 27.99% to -$2.3 million in 2020, then plummeted by 36.25% to -$3.1 million in 2021.
- Its last three reported values are -$3.1 million in Q4 2021, -$2.7 million for Q3 2021, and -$3.2 million during Q2 2021.